Recent Updates
Recently added Catalysts
LXEO Positive Sentiment Score: 85/100

Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Wednesday, January 3, 2024 1 min read
Key Takeaway: Lexeo Therapeutics, a clinical-stage genetic medicine company, is set to present at the 42nd Annual J.P. Morgan Healthcare Conference scheduled for January 10, 2024. CEO R. Nolan Townsend will deliver the presentation in San Francisco, showcasing the company's innovative approach to treating genetically defined cardiovascular diseases and Alzheimer's disease associated with APOE4. The event will be accessible via a live webcast on the company's website, with a replay available afterward. Lexeo's focus on applying pioneering science aims to significantly advance treatment options in their fields of expertise.

Market Sentiment Analysis

POSITIVE FACTORS

  • Lexeo Therapeutics is actively engaging the investment community through presentations.
  • The company's focus on groundbreaking treatments for significant health issues like Alzheimer's disease is promising.
  • The live presentation at a prestigious conference may enhance their visibility and attract potential investors.

Full Press Release Details

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 8:15 AM PT in San Francisco, California.
The event will be webcast live under the News & Events tab in the Investors section of the Company’s website. A replay of the webcast will be available after the conclusion of the live presentation.
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs.
janine.bogris@canalecomm.com
laurence@gilmartinir.com

Frequently Asked Questions

When will Lexeo Therapeutics present at the J.P. Morgan Healthcare Conference?

Lexeo Therapeutics will present on January 10, 2024, at 8:15 AM PT.

Where is the 42nd Annual J.P. Morgan Healthcare Conference held?

The conference will take place in San Francisco, California.

How can I access Lexeo's presentation online?

The presentation will be webcast live on the Company's website under News & Events.

What does Lexeo Therapeutics focus on?

Lexeo focuses on genetic medicine for cardiovascular diseases and Alzheimer's.

Is a replay of the presentation available?

Yes, a replay of the webcast will be available after the live presentation.

Tags: LXEO Viatris Investor Conferences Healthcare Lexeo Therapeutics J.P. Morgan cardiovascular diseases Alzheimer's disease
Last updated: Jan 3, 2024